| gap-pubmed-20260410- | What molecular mechanisms underlie the reversed STDP polarity in corticostriatal | open | 0.79 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How does YAP/TAZ loss promote anti-inflammatory environment while increasing mye | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms link YAP/TAZ to cGAS-STING and Wnt pathway modulation | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | Why does endothelial YAP/TAZ loss reduce stroke lesions when YAP/TAZ typically p | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | What explains the concordance between MB-FUS-enriched plasma cfDNA and disease t | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | How does MB-FUS-enhanced drug delivery correlate with actual tissue drug concent | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What mechanisms determine optimal timing and frequency of MB-FUS treatments for | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | How does lysosomal stress activation contribute to GBM cell death following SMPD | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What is the mechanistic link between SMPD1 inhibition, ceramide depletion, and E | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | Why does fluoxetine uniquely inhibit SMPD1 among SSRIs, and what structural feat | resolved | 0.87 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | How do exercise-induced biomarker changes causally relate to cognitive and motor | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link multimodal exercise to BDNF upregulation and cyto | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroplasticity |
| gap-pubmed-20260410- | How do shared cellular vulnerabilities lead to distinct proteinopathy phenotypes | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the low density distribution of NFTs and TDP-43 inclusions in CB | resolved | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do astrocytic plaques remain specific to CBD despite shared tau pathways wit | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How should degrader molecules be designed to effectively target protein aggregat | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What CNS-specific E3 ligases could enable brain-selective targeted protein degra | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can PROTAC and molecular glue degraders be engineered to achieve effective b | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does reduced SOD1 enzyme activity mechanistically link to specific metabolit | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms underlie the differential vulnerability of PMC vs FEF regions in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What functional consequences result from differential translation efficiency of | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the alternative β promoter regulate ApoD expression compared to the can | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive oxidative stress-specific expression of ApoD 5'U | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do combined astroglial and neuronal biomarker profiles predict individual PT | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | What mechanisms drive the overlap between PTSD biomarker patterns and neurodegen | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Can HCN1 inhibition prevent auditory deficits without disrupting normal developm | open | 0.79 | 0.00 | 2026-04-10 | 0 | | therapeutic-development |
| gap-pubmed-20260410- | Why are GABAergic interneurons selectively vulnerable to bilirubin toxicity comp | open | 0.76 | 0.00 | 2026-04-10 | 0 | | developmental-neurotoxicity |
| gap-pubmed-20260410- | What molecular mechanisms drive bilirubin's selective enhancement of HCN1 channe | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurotoxicity |
| gap-pubmed-20260410- | How does gentisic acid simultaneously modulate ferroptosis and oxidative phospho | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific molecular mechanisms mediate gentisic acid's neuroprotective effec | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the Vcp-Washc4 interaction specifically regulate autophagy versus other | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms explain why Washc4 deficiency causes ER stress while V | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which of the six identified active compounds are necessary and sufficient for th | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does XSD specifically enhance AMPK/SIRT1 signaling - direct activation or up | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the 52 PFAS-associated genes mechanistically connect prenatal exposure to | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which PFAS exposure alters PPAR an | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How does asparagine endopeptidase simultaneously regulate synaptic degeneration | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of GDF1's neuroprotective effects across differe | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does hearing loss specifically downregulate GDF1 expression in the hippocamp | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does Lewy pathology in LRRK2-PD specifically associate with non-motor sympto | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms mediate LRRK2 kinase activity's control of α-synuclein | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do RIPK1/RIPK3/MLKL specifically regulate mitochondrial permeability transit | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine compartment-specific activation of necroptos | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can therapeutic strategies be adapted to overcome age-related differences in | open | 0.82 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | What molecular mechanisms cause aged donor EVs to carry senescence signals that | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which therapeutic modalities are most effective during specific stages of the pr | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do blood-based biomarkers correlate with brain pathology during the preclini | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of OPTN's recognition of active Rab8a versus oth | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and c | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do neuronal exosome-derived α-synuclein levels decline longitudinally in PD | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |